<DOC>
	<DOCNO>NCT03080714</DOCNO>
	<brief_summary>To Compare agreement precision Topcon DRI OCT Triton 3D OCT-1 Maestro RDB .</brief_summary>
	<brief_title>Triton Agreement Precision Study</brief_title>
	<detailed_description>The objective study compare agreement precision Topcon DRI OCT Triton 3D OCT-1 Maestro RDB measure thickness layer .</detailed_description>
	<mesh_term>Eye Diseases</mesh_term>
	<criteria>Inclusion Criteria Normal Group 1 . Subjects 18 year age old date inform consent 2 . Subjects able understand write informed consent willing participate evidence signing inform consent 3 . Subjects present site normal eye bilaterally ( cataract acceptable ) 4 . IOP ≤ 21 mmHg bilaterally 5 . BCVA 20/40 well bilaterally Exclusion Criteria Normal Group 1 . Subjects unable tolerate ophthalmic imaging 2 . Subjects ocular medium sufficiently clear obtain acceptable OCT image 3 . HFA visual field ( 242 Sita Standard , white white ) result unreliable ( base manufacturer 's recommendation ) , define fixation loss &gt; 20 % false positives &gt; 33 % , false negative &gt; 33 % 4 . Visual field defect consistent glaucomatous optic nerve damage base least one follow two finding : 1 . On pattern deviation ( PD ) , exist cluster 3 point expect location visual field depress 5 % level , least 1 depressed 1 % level ; 2 . Glaucoma hemifield test `` outside normal limit . '' 5 . Narrow angle 6 . History leukemia , dementia multiple sclerosis 7 . Concomitant use hydroxychloroquine chloroquine Inclusion Criteria Glaucoma Group 1 . Subjects 18 year age old date inform consent 2 . Subjects able understand write informed consent willing participate evidence signing inform consent 3 . BCVA 20/40 good study eye 4 . Visual field defect consistent glaucomatous optic nerve damage base least one follow two finding : 1 . On pattern deviation ( PD ) , exist cluster 3 point expect location visual field depress 5 % level , least 1 depressed 1 % level ; 2 . Glaucoma hemifield test `` outside normal limit . '' 5 . Glaucomatous optic nerve damage evidence follow optic disc retinal nerve fiber layer structural abnormality : 1 . Diffuse thinning , focal narrowing , notch optic disc rim , especially inferior superior pole without disc hemorrhage ; 2 . Localized abnormality peripapillary retinal nerve fiber layer , especially inferior superior pole ; 3 . Optic disc neural rim asymmetry two eye consistent loss neural tissue Exclusion Criteria Glaucoma Group 1 . Subjects unable tolerate ophthalmic imaging 2 . Subject ocular medium sufficiently clear obtain acceptable OCT image 3 . HFA visual field ( 242 Sita Standard , white white ) result unreliable , defined fixation loss &gt; 20 % false positives &gt; 33 % , false negative &gt; 33 % study eye 4 . Presence ocular pathology except glaucoma study eye ( cataract acceptable ) 5 . History leukemia , dementia multiple sclerosis 6 . Concomitant use hydroxychloroquine chloroquine Inclusion Criteria Retina Disease Group 1 . Subjects 18 year age old date inform consent 2 . Subjects able understand write informed consent willing participate evidence signing inform consent 3 . Subjects present site retinal disease 4 . IOP ≤ 21 mmHg study eye 5 . BCVA 20/400 good study eye 6 . Diagnosis type retinal pathology investigator , may include , limited : Macular Degeneration , Diabetic Macular Edema , Diabetic Retinopathy , Macular Hole , Epiretinal Membrane , Cystoid Macula Edema , others Exclusion Criteria Retinal Disease Group 1 . Subjects unable tolerate ophthalmic imaging 2 . Subject ocular medium sufficiently clear obtain acceptable OCT image 3 . Presence glaucoma ocular pathology Retinal pathology ( e.g. , cornea pathology ) study eye ( cataract acceptable ) 4 . Narrow angle study eye 5 . History leukemia , dementia multiple sclerosis 6 . Concomitant use hydroxychloroquine chloroquine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>know ocular pathology</keyword>
	<keyword>Glaucoma</keyword>
	<keyword>Retinal Disease</keyword>
</DOC>